Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, α-cyano-β-hydroxy- β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13)

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 1, 2007, Pages 31-46

  Uckun, Fatih M ^a,b   Tibbles, Heather ^a   Venkatachalam, Taracad ^a   DuMez, Darin ^a   Erbeck, Douglas ^b  

^a Paradigm Pharmaceuticals   (United States)

^b Parker Hughes Cancer Center   (United States)

Author keywords

Anti leukemic agent; Bruton's tyrosine kinase inhibitor; CAS 244240 24 2; DDE 28; LFM A13, pharmacokinetics, preclinical studies; Cyano hydroxy methyl N (2,5 dibromophenyl) propenamide

Indexed keywords

ALPHA CYANO BETA HYDROXY BETA METHYL N (2,5 DIBROMOPHENYL) PROPENAMIDE; ANTILEUKEMIC AGENT; BRUTON TYROSINE KINASE; LEFLUNOMIDE; LFM A13; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG ELIMINATION; DRUG RESEARCH; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SUSPENSION;

EID: 33846820302     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296583     Document Type: Article

References (51)

1. Chessells JM, Veys P, Kempski H, Henley P, Leiper A, Webb D et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol. 2003;123(3):396-405.
2. Einsiedel HG, von Stackelberg A, Hartmann R, Fengler R, Schrappe M, Janka-Schaub G et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol. 2005;23(31):7942-7950.
3. Felix CA, Lange BJ, Chessells JM. Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000. Hematology (Am Soc Hematol Educ Program). 2000:285-302.
4. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579-587.
5. Barrett AJ, Horowitz MM, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994;331(19):1253-1258.
6. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
7. Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol. 1999;17(2):445-455.
8. Jacobsohn DA, Hewlett B, Ranalli M, Seshadri R, Duerst R, Kletzel M. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia. Bone Marrow Transplant. 2004;34(10):901-907.
9. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-1671.
10. Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol. 1997;15(6):2214-2221.
11. Uckun FM, Kersey JH, Haake R, Weisdorf D, Nesbit ME, Ramsay NK. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl J Med. 1993;329(18):1296-1301.
12. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG et al. Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer. 1998;83(9):2030-2039.
13. Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1997;90(1):28-35.
14. Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema NA et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood. 1998;91(3):735-746.
15. Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14(12):2257-2266.
16. Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol. 1998;101(1):94-103.
17. Gaynon P, Trigg M, Uckun FM. Childhood Acute Lymphoblastic Leukemia. In: Cancer Medicine Fourth Edition; 2000.
18. Uckun FM, Sudbeck EA, Mao C, Ghosh S, Liu XP, Vassilev AO et al. Structure-based design of novel anticancer agents. Curr Cancer Drug Targets. 2001;1(1):59-71.
19. Uckun FM, Mao C, Jan ST, Huang H, Vassilev AO, Sudbeck EA et al. SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity. Curr Opin Investig Drugs. 2000;1(2):252-256.
20. Uckun FM, Mao C, Vassilev AO, Navara CS, Narla RK, Jan ST. A rationally designed anticancer drug targeting a unique binding cavity of tubulin. Bioorg Med Chem Lett. 2000;10(10):1015-1018.
21. Fulda S, Debatin KM. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets. 2004;4(7):569-576.
22. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004;23(16):2950-2966.
23. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108(2):153-164.
24. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005;103(8):1551-1560.
25. Narla RK, Dong Y, Uckun FM. Apoptosis inducing novel anti-leukemic agent, bis(4,7-dimethyl-1,10 phenanthroline) sulfatooxovanadium(IV) [VO(SO4)(Me2-Phen) 2] depolarizes mitochondrial membranes. Leuk Lymphoma. 2001;41(5-6):625-634.
26. Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anticancer Agents. 2002;2(3):387-401.
27. Uckun FM, Waddick KG, Mahajan S, Jun X, Takata M, Bolen J et al. BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells. Science. 1996;273(5278):1096-1100.
28. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003;22(47):7414-7430.
29. Vassilev A, Ozer Z, Navara C, Mahajan S, Uckun FM. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex. J Biol Chem. 1999;274(3):1646-1656.
30. Uckun FM. Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol. 1998;56(6):683-691.
31. Mahajan S, Vassilev A, Sun N, Ozer Z, Mao C, Uckun FM. Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem. 2001;276(33):31216-3128.
32. Uckun FM, Mao C. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr Pharm Des. 2004;10(10):1083-1091.
33. Vassilev AO, Uckun FM. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK). Curr Pharm Des. 2004;10(15):1757-1766.
34. Vassilev AO, Tibbles HE, DuMez D, Venkatachalam TK, Uckun FM. Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors. Curr Drug Targets. 2006;7(3):327-343.
35. Feldhahn N, Rio P, Soh BN, Liedtke S, Sprangers M, Klein F et al. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci USA. 2005;102(37):13266-13271.
36. Mao C, Zhou M, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J Biol Chem. 2001;276(44):41435-41443.
37. Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem. 1999;274(14):9587-9599.
38. US Patent No. 6,160,010. Issued 12/12/2000. "BTK inhibitors and methods for their identification and use." Uckun FM, Zheng Y, Ghosh S.
39. US Patent No. 6,221,900. Issued 4/24/2001. "BTK inhibitors and methods for their identification and use." Uckun FM, Zheng Y, Ghosh S.
40. Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol. 2004;24(22):9986-9999.
41. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett. 2002;527(1-3):274-278.
42. Glassford J, Soeiro I, Skarell SM, Banerji L, Holman M, Klaus GG et al. BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene. 2003;22(15):2248-2259.
43. Fernandes MJ, Lachance G, Pare G, Rollet-Labelle E, Naccache PH. Signaling through CD16b in human neutrophils involves the Tec family of tyrosine kinases. J Leukoc Biol. 2005;78(2):524-532.
44. Uckun FM, Zheng Y, Cetkovic-Cvrlje M, Vassilev A, Lisowski E, Waurzyniak B et al. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5- dibromophenyl) propenamide (LFM-A13), a novel anti-leukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res. 2002;8(5):1224-1233.
45. Cetkovic-Cvrlje M, Uckun FM. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model. Br J Haematol. 2004;126(6):821-827.
46. Tibbles H, Vassilev A, Uckun FM. A dual function anti-leukemic agent with anti-thrombotic activity. Leuk Lymphoma. 2002;43(5):1121-1127.
47. Uckun FM, Vassilev A, Bartell S, Zheng Y, Mahajan S, Tibbles HE. The anti-leukemic Bruton's tyrosine kinase inhibitoralpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. Leuk Lymphoma. 2003;44(9):1569-1577.
48. Tibbles HE, Samuel P, Erbeck D, Mahajan S, Uckun FM. In vivo toxicity and antithrombotic profile of the oral formulation of the anti-leukemic agent, LFM-A13-F. Arzneimittel-Forschung (Drug Research). 2004;54(6):330-339.
49. Redondo PC, Ben-Amor N, Salido GM, Bartegi A, Pariente JA, Rosado JA. Ca2+-independent activation of Bruton's tyrosine kinase is required for store-mediated Ca2+ entry in human platelets. Cell Signal. 2005;17(8):1011-1021.
50. Redondo PC, Harper MT, Rosado JA, Sage SO. A role for cofilin in the activation of store-operated calcium entry by de novo conformational coupling in human platelets. Blood. 2006;107(3):973-979.
51. Crosby D, Poole AW. Interaction of Bruton's tyrosine kinase and protein kinase Ctheta in platelets. Cross-talk between tyrosine and serine/threonine kinases. J Biol Chem. 2002;277(12):9958-9965.